Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
29 mai 2024 08h25 HE
|
Stereotaxis, Inc.
The most advanced robotic cardiac ablation lab opens at Penn Presbyterian Medical Center.
ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
29 mai 2024 08h00 HE
|
Oryzon Genomics, S.A.
Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and SpainOryzon to validate epigenetic agents by applying a personalized medicine...
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
28 mai 2024 08h00 HE
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
24 mai 2024 07h30 HE
|
BridgeBio Pharma, Inc.
- BridgeBio to host investor call on Wednesday, May 29, 2024 at 5:30 pm ET, with presentations from Mathew Maurer, M.D. of Columbia University Irving Medical Center, U.S. and Ahmad Masri, M.D., M.S....
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23 mai 2024 17h13 HE
|
SpringWorks Therapeutics, Inc.
– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation – – Additional data and analyses from Phase 3 DeFi trial of OGSIVEO®...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
23 mai 2024 17h05 HE
|
Cogent Biosciences, Inc.
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
23 mai 2024 17h01 HE
|
Cogent Biosciences, Inc.
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging...
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
23 mai 2024 17h00 HE
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
23 mai 2024 17h00 HE
|
Werewolf Therapeutics, Inc.
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - ...
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
22 mai 2024 10h23 HE
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.